UNRESECTABLE SOLID TUMOR
Clinical trials for UNRESECTABLE SOLID TUMOR explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE SOLID TUMOR trials appear
Sign up with your email to follow new studies for UNRESECTABLE SOLID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancers with rare mutation
Disease control Recruiting nowThis early-phase study tests a new drug, CLSP-1025, in adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have a specific genetic change called p53 R175H and a certain immune type (HLA-A*02:01). The goal is to find a safe dose and see if the drug can …
Matched conditions: UNRESECTABLE SOLID TUMOR
Phase: PHASE1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control
Last updated May 16, 2026 22:29 UTC
-
New targeted drug hopes to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called FMC-376 in people with advanced solid tumors that have a specific genetic change (KRAS G12C). The goal is to find a safe dose and see if the drug can shrink tumors. About 400 adults whose cancer has worsened after standard treatments w…
Matched conditions: UNRESECTABLE SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Frontier Medicines Corporation • Aim: Disease control
Last updated May 16, 2026 22:29 UTC
-
New pill targets Hard-to-Treat cancers with PIK3CA mutation
Disease control Recruiting nowThis early-phase study tests an experimental oral drug, RGT-490, in adults with advanced solid tumors (including breast, ovarian, and endometrial cancers) that have a specific genetic change called PIK3CA. The main goals are to check the drug's safety, find the right dose, and se…
Matched conditions: UNRESECTABLE SOLID TUMOR
Phase: PHASE1 • Sponsor: Regor Pharmaceuticals Inc. • Aim: Disease control
Last updated May 16, 2026 22:26 UTC
-
Nanoparticle radiation therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment called 177Lu-SN201 for people with advanced solid tumors that have not responded to standard therapies. The treatment uses tiny particles that deliver radiation directly to tumors. The goal is to find the safest dose and see if it can shrink tumor…
Matched conditions: UNRESECTABLE SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Spago Nanomedical AB • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New drug targets Hard-to-Treat cancers with specific gene mutation
Disease control Recruiting nowThis early-stage study tests a new drug, RLY-2608, designed to block a faulty protein in cancer cells with a specific gene change (PIK3CA mutation). It is for adults with advanced solid tumors or certain breast cancers that have not responded to other treatments. The study will t…
Matched conditions: UNRESECTABLE SOLID TUMOR
Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 04, 2026 16:20 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests whether combining two drugs, afatinib and pemigatinib, is safe and can shrink tumors in people with advanced solid cancers that have certain genetic changes (FGFR alterations). About 70 adults whose standard treatments have stopped working will take part. The mai…
Matched conditions: UNRESECTABLE SOLID TUMOR
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
Proton GRID: a new way to shrink tough tumors and ease pain?
Symptom relief Recruiting nowThis study tests a special type of proton radiation called GRID for people with large or previously treated tumors that cannot be removed. The goal is to safely relieve symptoms like pain. About 24 adults will receive three radiation sessions. Researchers will check for side effe…
Matched conditions: UNRESECTABLE SOLID TUMOR
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Symptom relief
Last updated May 16, 2026 22:32 UTC